Neuroimaging Core

神经影像核心

• 批准号: 10228130
• 负责人: KEJAL KANTARCI
• 金额: $ 1.98万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-15 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10228130
• 关键词: Alzheimer' s Disease; Biological Markers; Brain; Brain imaging; C9ORF72; Clinical; Clinical Trials; Clinical Trials Cooperative Group; Communities; Confidentiality of Patient Information; Consult; Cross-Sectional Studies; Data; Data Analyses; Dementia; Development; Diagnosis; Diagnostic; Diffusion; Disease; Ensure; Ethics; Frontotemporal Lobar Degenerations; Functional Magnetic Resonance Imaging; Funding; Future; Genes; Genetic; Goals; Image; Image Analysis; Imaging technology; Individual; Laboratories; Leadership; Light; Longitudinal Studies; MRI Scans; Magnetic Resonance Imaging; Measurement; Measures; Nerve Degeneration; Neurodegenerative Disorders; Participant; Patients; Perfusion; Pharmaceutical Preparations; Preparation; Procedures; Process; Protocols documentation; Quality Control; Recording of previous events; Research; Research Personnel; Research Project Grants; Resources; Role; Scanning; Site; Staging; Standardization; Structure; Symptoms; Testing; Work; catalyst; clinical research site; cohort; data management; data sharing; design; experience; image archival system; image processing; imaging biomarker; imaging study; innovation; innovative technologies; multimodality; mutation carrier; neuroimaging; neuropathology; programs; tool

ABSTRACT – ARTFL LEFFTDS Longitudinal FTLD: NEUROIMAGING CORE Brain imaging has taken on critical roles in dementia research, including its use for diagnosis and staging of multiple neurodegenerative disorders and enrichment of study groups for clinical trials. In the earliest stages of neurodegenerative disease, when symptoms have not yet developed, imaging and other biomarkers may be the only disease indicators that can be used to quantify drug effects in clinical trials, and imaging may ultimately guide use of approved treatments. The goal of this project is to create a neuroimaging core for the ARTFL LEFFTDS Longitudinal FTD (ALLFTD) project. The core will ensure optimal quality and efficient, innovative use of brain images collected for the project by designing and ensuring faithful application of a standardized acquisition protocol across the 19 clinical sites and promoting the application of advanced imaging technology in the FTLD field. We will design acquisition protocols that optimally utilize the scanner capabilities for the advanced sequences at each study site and allow harmonization of images across the study. All scans, along with the quality control information, will be made available to the public through the Laboratory of Neuroimaging (LONI). We will provide innovative technology and resources for understanding the contribution of MAPT, GRN or C9orf72 genes to neurodegeneration in FTLD and reliable estimates of changes in cortical volume in asymptomatic and symptomatic mutation carriers as well as patients with sporadic FTLD, in preparation for future clinical trials. We will provide resources for establishing the topographic distribution of brain structural changes across the FTLD spectrum, and work with LONI to maintain an archive of images and establish appropriate processes to ensure ethical and efficient access to the data. The Neuroimaging Core will pursue the following aims: 1) Establish and maintain a harmonized MRI acquisition protocol for acquisition and quality control of T1, FLAIR, T2, diffusion, ASL-perfusion, and task free functional MRI across 19 participating sites and supply MRI scans for research projects and the research community, while protecting patient confidentiality. 2) Operate a standardized quality control, image processing and data analysis program. 3) Supply processed cross-sectional and longitudinal data including regional cortical volume measurements and longitudinal change in cortical volume on serial MRIs for ALLFTD Projects 1 and 2, and also share these data with the research community. 4) Consult with ALLFTD and outside researchers and share research tools to facilitate use of imaging data for analysis. The leaders of this proposed neuroimaging core have extensive experience with image analysis and leadership of multicenter imaging efforts, including the Alzheimer's Disease Neuroimaging Initiative (ADNI), which set the standard for multisite imaging studies in dementia. This will help to ensure smooth conduct of the imaging activities for ALLFTD.

摘要-ARTFL LEFFTDS纵向FTLD：神经成像核心 脑成像在痴呆症研究中发挥了关键作用，包括用于诊断和分期 多个神经退行性疾病和丰富的研究小组进行临床试验。在…的最早阶段 神经退行性疾病，当症状尚未发展时，影像和其他生物标志物可能 在临床试验中，唯一可以用来量化药物效果的疾病指标，以及成像可能 最终指导批准的治疗方法的使用。这个项目的目标是创建一个神经成像核心 LEFFTDS纵向FTD(ALLFTD)项目。核心将确保最佳质量和效率， 创新地使用为项目收集的脑图像，通过设计和确保忠实应用 跨19个临床站点的标准化采集方案，并推广先进的 FTLD领域的成像技术。我们将设计最佳利用扫描仪的采集协议 每个研究站点的高级序列的功能，并允许协调整个 学习。所有扫描资料，连同品质控制资料，将透过 神经成像实验室(LONI)我们将提供创新的技术和资源来了解 MAPT、GRN或C9orf72基因在FTLD神经退行性变中的作用及可靠估计 无症状突变携带者和有症状突变携带者的皮质体积变化 零星FTLD，为未来的临床试验做准备。我们会提供资源，成立 FTLD频谱上大脑结构变化的地形分布，并与LONI合作保持 建立图像档案，并建立适当的程序，以确保合乎道德和高效地获取数据。 神经成像核心将追求以下目标：1)建立和维护协调的磁共振成像 用于T1、FLAIR、T2、弥散、ASL灌注和无任务采集和质量控制的采集协议 19个参与站点的功能磁共振成像，并为研究项目和研究提供MRI扫描 社区，同时保护患者的机密性。2)运行标准化的质量控制、图像处理 和数据分析程序。3)提供经处理的横断面和纵向数据，包括区域 ALLFTD项目系列磁共振成像的皮质体积测量和纵向变化 1和2，并与研究社区共享这些数据。4)咨询ALLFTD和外部 研究人员和共享研究工具，以促进使用成像数据进行分析。这个组织的领导人 推荐的神经成像核心具有丰富的图像分析和多中心领导经验 成像努力，包括阿尔茨海默病神经成像倡议(ADNI)，该倡议为 痴呆的多部位影像研究。这将有助于确保成像活动的顺利进行 一切都好。